How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Guidance assessment consultation document for GID-HTE10059 Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: Early Value Assessment

Closed for comments This consultation ended on at   Request commenting lead permission

Guidance development process

NICE early value assessment (EVA) guidance provides recommendations on promising health technologies that have the potential to address national unmet need. NICE has assessed early evidence on these technologies to determine if earlier patient and system access in the NHS is appropriate while further evidence is generated.

EVA guidance recommendations are conditional while more evidence is generated to address uncertainty in their evidence base. NICE has included advice in this guidance on how to minimise any clinical or system risk of early access to treatment.

Further evidence will be generated over the next 3 years to assess if the benefits of these technologies are realised in practice. NICE guidance will be reviewed to include this evidence and make a recommendation on the routine adoption of this technology across the NHS. Find out more on the NICE webpage on early value assessment (EVA) for medtech.

NICE is producing this guidance on AI technologies for the opportunistic detection of vertebral fragility fractures in the NHS in England. The diagnostics advisory committee has considered the evidence and the views of clinical and patient experts.

This document has been prepared for consultation with the stakeholders. It summarises the evidence and views that have been considered, and sets out the recommendations made by the committee. NICE invites comments from the stakeholders for this evaluation and the public. This document should be read along with the evidence.

The committee is interested in receiving comments on the following:

  • Has all of the relevant evidence been taken into account?

  • Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

After consultation:

  • Based on the consultation comments received, the committee may meet again.

  • If committee meets again it will consider the evidence, this evaluation consultation document and comments from stakeholders.

  • The committee will then prepare the final draft guidance, which will go through a resolution process before the final guidance is agreed.

Note that this document is not NICE's final guidance on AI technologies for the opportunistic detection of vertebral fragility fractures. The recommendations in section 1 may change after consultation. More details are available in NICE's health technology evaluations: the manual and NICE's early value assessment interim process and methods statement.

Key dates:

Closing date for comments: 29 July 2025